[Stem Cell Reviews and Reports] MSC therapy has gained interest as a disease-modifying strategy because its therapeutic activity appears to depend largely on paracrine signaling rather than durable engraftment. Through these mechanisms, MSCs may suppress profibrotic fibroblast activation, and recalibrate innate and adaptive immune responses.

[Cell] Researchers conducted a first-in-human clinical trial involving a single intravenous infusion of glycocalyx-edited autologous bone marrow-derived MSCs in ten women with advanced-stage osteoporosis

[Small] Scientists revealed that bifunctional carbon dots restore MSC function by reactivating autophagic flux, thereby simultaneously enhancing osteogenic differentiation and immunomodulatory capacity.

[Scientific Reports] The authors presented the first investigation of scaffold-free, defined-media differentiation of olfactory mucosa-derived MSCs (OM-MSCs) towards a Schwann cell (SC)-like phenotype. They highlight the potential of OM-MSCs to be expanded and differentiated to SCs to improve synthetic scaffolds.

[International Journal of Oral Science] Researchers observed a significant decrease in insulin-like growth factor binding protein 5 (IGFBP5) expression in dental follicle stem cells undergoing replicative or H₂O₂-induced senescence.

[Ernexa Therapeutics] Ernexa Therapeutics announced preliminary preclinical results for ERNA-201, its synthetic, allogeneic induced MSC therapy engineered to express anti inflammatory factors.

[Scientific Reports] Investigators evaluated the effects of retinoic acid-treated human umbilical cord-derived MSCs on Alzheimer’s disease-associated pathological and functional changes in a mouse model of Alzheimer’s disease.

[Cell Stem Cell] Researchers presented a stiffness-responsive MSC-assisted relayed tumor-targeting platform that converts matrix stiffness into a programmable molecular entry point for radiotheranostics. This platform is readily adaptable to alternative synthetic targets and iPSC-derived MSCs.

[Athernal Bio (BioSpace)] Athernal Bio announced it has been awarded a grant of nearly £700,000 through Innovate UK’s Growth Catalyst - Investor Partnerships program. The funding will accelerate the development of Athernal’s immunotherapy program, designed to intercept the earliest stages of AML.

[Nature Genetics] Researchers studied HSCs, progenitors, and immune cells from patients with myeloproliferative neoplasms at baseline and following IFNα treatment. They deployed single-cell multiomics methods that distinguish the IFNα effects on mutated stem cells from the admixed wild-type HSC.

[NPJ Precision Oncology] By constructing a single-cell transcriptional metabolic landscape, investigators identified the tricarboxylic acid cycle as the dominant source of metabolic heterogeneity in leukemic cells, enabling their stratification into three distinct states.

[Stem Cell Reports] Through cell-cell communication analysis of bone marrow single-cell sequencing data, researchers identified the Notch ligand Delta-like protein 1 (DLL1) as a potential regulator in hematopoietic stem and progenitor cell asymmetric division.